13 matokeo
The present disclosure relates to the fields of pharmaceutical and organic chemistry, and provides 4,5-dihydro-(1H)-pyrazole (pyrazoline) derivatives as cannabinoid CB.sub.1 receptor modulators, intermediates for synthesizing these compounds, formulations comprising these compounds, methods for
RELATED APPLICATION
This application is a national stage filing under 35 U.S.C. .sctn.371 of international application PCT/GB2014/051159, filed Apr. 14, 2014, which was published under PCT Article 21 (2) in English
The present invention relates to the use of tetrahydrocannabivarin (THCV) in the
2. FIELD OF THE INVENTION
The present invention relates to Proline Analog Compounds that are ligands for cannabinoid receptors, compositions comprising a Proline Analog Compound and a pharmaceutically-acceptable carrier, methods of making such Proline Analog Compounds, and methods for treating or
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority to pending U.S. application Ser. No. 14/561,091 entitled "Transdermal Cannabinoid Formulations", filed Dec. 4, 2014, now U.S. Pat. No. 9,375,417, issued Jun. 28, 2016, the disclosure of which is hereby incorporated by reference
BACKGROUND
The clinical usefulness of the cannabinoids, including 11.sup.9-tetrahydrocannabinol (/1.sup.9-THC), to provide analgesia, help alleviate nausea and emesis, as well as stimulate appetite has been well-recognized. Cannabinoids offer a variety of pharmacological benefits, including, but not
BACKGROUND
The clinical usefulness of the cannabinoids, including .DELTA..sup.9-tetrahydrocannabinol (.DELTA..sup.9-THC), to provide analgesia, help alleviate nausea and emesis, as well as stimulate appetite has been well-recognized. Cannabinoids offer a variety of pharmacological benefits,
BACKGROUND OF THE INVENTION
This invention relates to certain novel octahydro-3-alkoxy-9-alkyl-phenanthridines and derivatives thereof and pharmaceutically acceptable acid addition salts thereof useful as antiinflammatory, analgesics, immunosuppressive, antiemetic and intraocular pressure reducing
BACKGROUND OF THE INVENTION
Field of the Invention
This invention relates to suppository formulations for medical use. The suppository may be applied to human cavities other than the oral cavity. This suppository provides efficient absorption of active ingredients while avoiding unpleasant taste
BACKGROUND OF THE INVENTION
Field of the Invention
This invention relates to suppository formulations for medical use. The suppository may be applied to human cavities other than the oral cavity. This suppository provides efficient absorption of active ingredients while avoiding unpleasant taste
FIELD OF THE INVENTION
The present invention relates generally to processes for the preparation of pharmaceutical compounds and compositions useful in the treatment of disorders and diseases of the central nervous system (CNS). More specifically, the present invention relates to the preparation of
FIELD
This disclosure generally relates to antagonists of the cannabinoid (CB)1 G-protein coupled receptor (CB1), particularly certain neutral antagonists. Such compounds have a range of useful applications including use to treat certain medical conditions with no or substantially reduced incidence
FIELD OF THE INVENTION
The present invention relates in general to methods for delivering therapeutic compounds across the blood-brain barrier of patients, and more particularly to the use of cannabinoids coupled to a chemotherapy agent for transport across the blood-brain barrier.
BACKGROUND OF THE
FIELD
Disclosed here are compositions comprising powdered hemp seed, an emulsifier/dispersant such as lecithin (particularly soy lecithin), cannabis, and optionally other additives and excipients. Also described are methods of making the compositions. The compositions may be used, for instance, in